AVACTA GROUP PLC — Board/Management Information 2025

Apr 29, 2025

National Storage Mechanism | Additional information

RNS Number : 5158G

Avacta Group PLC

29 April 2025

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Board change

LONDON and PHILADELPHIA - April 29, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that Dr. Trevor Nicholls, one of the Group's non-executive directors, is retiring from the Board with effect from April 30, 2025. 

Mark Goldberg will take over as the Board's Chair of the Remuneration Committee

Shaun Chilton, non-executive Chairman commented:

"On behalf of the Avacta Board, I would like to thank Trevor for his valued contribution and dedication to the Company since his appointment in 2013 and wish him all the best for the future.

"As Avacta transitions to a pure-play biotechnology company, we have initiated the process of appointing an independent non-executive director with relevant international commercial experience and expertise. A further announcement will be made in due course."

For further information from Avacta Group plc, please contact:

Avacta Group plc Michael Vinegrad, Group Communications Director	www.avacta.com
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden	www.peelhunt.com
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert	www.panmureliberum.com [email protected]
Investor Contact Renee Leck THRUST Strategic Communications	[email protected]
Media Contact Carly Scaduto Carly Scaduto Consulting	[email protected]

About Avacta -  www.avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAPPUACCUPAGBR